GALT
NASDAQ · Biotechnology
Galectin Therapeutics Inc
$3.46
+0.32 (+10.19%)
Analyst Consensus
Strong Buy
7
Analysts
Moderate
Coverage
Price Target
Analyst Price Target
+274.6% upside
Low Target
$9.51
Average Target
$12.96
High Target
$17.52
Current Price
$3.46
Current
$3.46
$3.46
Target
$12.96
$12.96
$9.51
$12.96 avg
$17.52
Scenario Analysis
Bear Case
$9.51
174.9%
Low target
Base Case
$12.96
+274.6%
Avg target
Bull Case
$17.52
+406.4%
High target
Risk/Reward
2.3x
Favorable
Price in Context
52-Week High
$7.13
-51.5% from high
52-Week Low
$2.03
+70.9% from low
Target vs 52W High
$12.96
+81.8% vs high
Next Earnings Report
Nov 16, 2026
2d
until earnings
EPS Est: $-0.05
Earnings in 2 days. Analyst targets may shift significantly after the report.
Peer Consensus — Biotechnology
| Stock | Consensus | Analysts | Buy % | Target | Upside |
|---|---|---|---|---|---|
| ABBV | Strong Buy | 38 | 82% | $257.58 | -12.5% |
| AMGN | Hold | 42 | 43% | $190.87 | -59.0% |
| GILD | Strong Buy | 36 | 83% | $362.68 | +115.4% |
| VRTX | Strong Buy | 39 | 82% | $438.34 | -18.5% |
| MRNA | Hold | 31 | 32% | $149.45 | -35.4% |
| REGN | Buy | 36 | 72% | $76.80 | -91.9% |
| NTRA | Strong Buy | 31 | 90% | $142.91 | -55.7% |
| RVMD | Strong Buy | 31 | 94% | $114.11 | -35.3% |